Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Surgical Outcome of Borderline Resectable Pancreatic Cancer: Upfront Surgery Versus Neoadjuvant Chemotherapy (Single Center Experience)

NCT06206382 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT06206382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06206382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Surgical Outcome of Borderline Resectable Pancreatic Cancer: Upfront Surgery Versus Neoadjuvant Chemotherapy (Single Center Experience)
Lead sponsor
Assiut University
Phase
Observational
Overall status
Unknown status
Start date
January 5, 2024
Completion date
October 31, 2025
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer